Shanghai Cell Therapy Group Co., Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD19, CD22, and BCMA (tri-antigen)Cell therapy | Systemic Lupus Erythematosus | |
| Phase 1 | CD19, CD20, and BCMA (tri-target)Cell therapy | Multiple Myeloma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.